as 05-30-2025 4:00pm EST
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Founded: | 2008 | Country: | Netherlands |
Employees: | N/A | City: | N/A |
Market Cap: | 35.3B | IPO Year: | 2017 |
Target Price: | $698.22 | AVG Volume (30 days): | 493.8K |
Analyst Decision: | Strong Buy | Number of Analysts: | 20 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 15.94 | EPS Growth: | N/A |
52 Week Low/High: | $359.37 - $678.21 | Next Earning Date: | 05-08-2025 |
Revenue: | $2,643,062,000 | Revenue Growth: | 82.13% |
Revenue Growth (this year): | 61.64% | Revenue Growth (next year): | 32.00% |
ARGX Breaking Stock News: Dive into ARGX Ticker-Specific Updates for Smart Investing
TipRanks
2 days ago
GlobeNewswire
3 days ago
MT Newswires
3 days ago
Insider Monkey
18 days ago
Zacks
19 days ago
Morningstar Research
22 days ago
Insider Monkey
22 days ago
GuruFocus.com
23 days ago
The information presented on this page, "ARGX argenx SE - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.